MDT

95.88

+0.38%↑

VEEV

287.01

+0.02%↑

A

139.46

+2.12%↑

HQY

92.33

+1.94%↑

PHR.US

22.06

-1.16%↓

MDT

95.88

+0.38%↑

VEEV

287.01

+0.02%↑

A

139.46

+2.12%↑

HQY

92.33

+1.94%↑

PHR.US

22.06

-1.16%↓

MDT

95.88

+0.38%↑

VEEV

287.01

+0.02%↑

A

139.46

+2.12%↑

HQY

92.33

+1.94%↑

PHR.US

22.06

-1.16%↓

MDT

95.88

+0.38%↑

VEEV

287.01

+0.02%↑

A

139.46

+2.12%↑

HQY

92.33

+1.94%↑

PHR.US

22.06

-1.16%↓

MDT

95.88

+0.38%↑

VEEV

287.01

+0.02%↑

A

139.46

+2.12%↑

HQY

92.33

+1.94%↑

PHR.US

22.06

-1.16%↓

Search

Erasca Inc

Abierto

2.4 -0.41

Resumen

Variación precio

24h

Actual

Mínimo

2.39

Máximo

2.44

Métricas clave

By Trading Economics

Ingresos

-2.9M

-34M

Margen de beneficios

-768.16

Empleados

103

EBITDA

-2.5M

-38M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+34.85% upside

Dividendos

By Dow Jones

Próximas Ganancias

10 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

242M

661M

Apertura anterior

2.81

Cierre anterior

2.4

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Erasca Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 oct 2025, 21:50 UTC

Adquisiciones, fusiones, absorciones

Caterpillar to Acquire Australia's RPM Global for $730 Million

10 oct 2025, 21:38 UTC

Adquisiciones, fusiones, absorciones

Strathcona Resources Terminates Take-Over Bid for MEG Energy

12 oct 2025, 23:47 UTC

Charlas de Mercado

Gold Rises, Buoyed by Monetary Debasement Fears -- Market Talk

12 oct 2025, 23:39 UTC

Charlas de Mercado

Oil Rises on Likely Technical Recovery, Mildly Positive Sentiment -- Market Talk

12 oct 2025, 23:22 UTC

Charlas de Mercado

New Zealand Braces For Renewed Trade War Uncertainty -- Market Talk

12 oct 2025, 23:16 UTC

Adquisiciones, fusiones, absorciones

Caterpillar Inc. Enters Into Agreement To Acquire RPMGlobal >CAT RUL.AU

12 oct 2025, 22:32 UTC

Charlas de Mercado

Copper, U.S. Thermal Coal Stand Out as Metals Ride Macro Tailwinds -- Market Talk

12 oct 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

RPM Global Says Board Unanimously Recommends Shareholders Accept Caterpillar Offer

12 oct 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

RPM Global Agrees to Takeover by Caterpillar

12 oct 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

RPM Global Says Caterpillar Offering A$5.00/Share in Cash

11 oct 2025, 08:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

11 oct 2025, 00:18 UTC

Adquisiciones, fusiones, absorciones

Why Biotech May Be Back -- Barrons.com

10 oct 2025, 21:07 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Dell Is Just Beginning to Tell Its AI Story. Buy the Stock. -- Barrons.com

10 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

10 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

10 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

10 oct 2025, 20:06 UTC

Charlas de Mercado

Fed Won't Publish Monthly Industrial Data Next Week -- Market Talk

10 oct 2025, 20:06 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 oct 2025, 19:56 UTC

Charlas de Mercado

U.S.-China Tension Weighs Down on Treasury Yields, Dollar -- Market Talk

10 oct 2025, 19:20 UTC

Charlas de Mercado

Oil Futures Sink As Trump Rekindles Trade Tensions -- Market Talk

10 oct 2025, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Weekly Loss -- Market Talk

10 oct 2025, 18:58 UTC

Charlas de Mercado

Canada's Jobs Gain Marks a 'Head Fake' For Economy -- Market Talk

10 oct 2025, 18:52 UTC

Charlas de Mercado

PepsiCo Lays Groundwork for Improvement -- Market Talk

10 oct 2025, 18:47 UTC

Charlas de Mercado

Precious Metals Turn Higher After Profit-Taking Slide -- Market Talk

10 oct 2025, 18:35 UTC

Charlas de Mercado

Canada's Next Rate Cut May be Pushed to December -- Market Talk

10 oct 2025, 18:31 UTC

Charlas de Mercado

Canada's Labor Market Firming. But Conditions Vary Across Country -- Market Talk

10 oct 2025, 17:32 UTC

Charlas de Mercado

U.S. Oil Rig Count Declines by Four to 418 -- Market Talk

10 oct 2025, 16:55 UTC

Ganancias

These Stocks Are Moving the Most Today: MP Materials, Nvidia, Alibaba, Venture Global, Applied Digital, Qualcomm, and More -- Barrons.com

10 oct 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

10 oct 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Erasca Inc previsión

Precio Objetivo

By TipRanks

34.85% repunte

Estimación a 12 Meses

Media 3.25 USD  34.85%

Máximo 6 USD

Mínimo 1 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

2

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

1.39 / 1.44Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Very Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
help-icon Live chat